

Bernard Zinman Cm

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2414078/bernard-zinman-cm-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

254
papers

37,683
citations

72
h-index

193
g-index

268
ext. papers

46,005
ext. citations

11.4
avg, IF

7.24
L-index

#	Paper	IF	Citations
254	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015 , 373, 2117-28	59.2	6064
253	Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. <i>New England Journal of Medicine</i> , 2005 , 353, 2643-53	59.2	3690
252	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 311-22	59.2	3606
251	Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>New England Journal of Medicine</i> , 2006 , 355, 2427-43	59.2	2332
250	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
249	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 323-34	59.2	1956
248	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 1228-1239	59.2	1017
247	Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). <i>Diabetes Care</i> , 2009 , 32, 1224-30	14.6	691
246	Liraglutide and Renal Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 839-848	59.2	599
245	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 69-79	27.4	562
244	Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). <i>Diabetes Care</i> , 2008 , 31, 845-51	14.6	431
243	Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. <i>New England Journal of Medicine</i> , 2011 , 365, 2366-76	59.2	390
242	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018 , 41, 356-363	14.6	365
241	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017 , 377, 723-732	59.2	349
240	The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. <i>Annals of Internal Medicine</i> , 2007 , 146, 477-85	8	343
239	Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. <i>Diabetes</i> , 2008 , 57, 995-1001	0.9	340
238	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 105-113	18.1	336

237	Insulins today and beyond. <i>Lancet, The</i> , 2001 , 358, 739-46	40	312
236	Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 45-53	27.4	290
235	Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?. <i>Diabetes Care</i> , 2005 , 28, 600-6	14.6	287
234	SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 90-100	3.3	283
233	Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. <i>Lancet, The</i> , 2014 , 384, 2228-34 ⁴⁰	40	278
232	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
231	Insulin degludec versus insulin glargine in insulin-naïve patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). <i>Diabetes Care</i> , 2012 , 35, 2464-71	14.6	263
230	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018 , 137, 119-129	16.7	252
229	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1155-1166	27.4	245
228	Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. <i>Obesity</i> , 2008 , 16, 1901-7	8	243
227	Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. <i>Archives of Internal Medicine</i> , 2011 , 171, 412-20		238
226	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2017 , 5, 610-621	18.1	217
225	Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. <i>Diabetes Care</i> , 2010 , 33, 1536-43	14.6	207
224	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Circulation</i> , 2019 , 140, 1693-1702	16.7	205
223	Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. <i>Diabetes Care</i> , 2014 , 37, 1480-3	14.6	186
222	Overweight among children and adolescents in a Native Canadian community: prevalence and associated factors. <i>American Journal of Clinical Nutrition</i> , 2000 , 71, 693-700	7	184
221	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA ²). <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 164-74	3.3	182
220	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. <i>Lancet, The</i> , 2010 , 376, 103-11	40	178

219	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME ² trial. <i>European Heart Journal</i> , 2018 , 39, 363-370	9.5	171
218	Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. <i>American Heart Journal</i> , 2013 , 166, 823-30.e5	4.9	162
217	Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. <i>Diabetes</i> , 2013 , 62, 3976-86	0.9	162
216	Glucoregulation during moderate exercise in insulin treated diabetics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1977 , 45, 641-52	5.6	155
215	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME ²) <i>Cardiovascular Diabetology</i> , 2014 , 13, 102	8.7	153
214	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017 , 46, 462-472	4.6	149
213	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. <i>Diabetes Care</i> , 2018 , 41, 2560-2569	14.6	149
212	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019 , 140, 739-750	16.7	140
211	Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 134-42	5.6	138
210	Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 28-34	18.1	129
209	Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. <i>Diabetes Care</i> , 2016 , 39, 1702-10	14.6	126
208	Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. <i>Diabetes</i> , 2004 , 53, 3193-200	0.9	124
207	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , 2013 , 10, 289-301	3.3	119
206	Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018 , 41, e4-e5	14.6	116
205	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2020 , 141, 704-707	16.7	115
204	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. <i>Circulation</i> , 2019 , 139, 1384-1395	16.7	115
203	Common and rare ABCA1 variants affecting plasma HDL cholesterol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 1983-9	9.4	113
202	Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. <i>Diabetes Care</i> , 2015 , 38, 132-9	14.6	110

201	The physiologic replacement of insulin. An elusive goal. <i>New England Journal of Medicine</i> , 1989 , 321, 363-70	59.2	110
200	Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2011 , 377, 924-31	40	107
199	Prospective associations of vitamin D with β cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. <i>Diabetes</i> , 2011 , 60, 2947-53	0.9	103
198	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019 , 139, 351-361	16.7	103
197	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2017 , 40, 777-783	14.6	102
196	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 356-367	18.1	102
195	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). <i>Diabetologia</i> , 2018 , 61, 48-57	10.3	101
194	Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME \square trial. <i>Diabetologia</i> , 2018 , 61, 2155-2163	10.3	100
193	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. <i>Diabetologia</i> , 2018 , 61, 58-65	10.3	98
192	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. <i>Circulation</i> , 2018 , 137, 405-407	16.7	96
191	Liraglutide and the preservation of pancreatic β cell function in early type 2 diabetes: the LIBRA trial. <i>Diabetes Care</i> , 2014 , 37, 3270-8	14.6	89
190	Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. <i>Clinical Science</i> , 1996 , 90, 189-95	6.5	88
189	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017 , 48, 1218-1225	6.7	86
188	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , 2019 , 42, 2262-2271	14.6	82
187	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. <i>Diabetes Care</i> , 2015 , 38, 793-800	14.6	82
186	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2755-2769	12.7	81
185	Fetal sex and maternal risk of gestational diabetes mellitus: the impact of having a boy. <i>Diabetes Care</i> , 2015 , 38, 844-51	14.6	78
184	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. <i>Circulation</i> , 2018 , 138, 1904-1907	16.7	75

183	Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3373-7	5.6	72
182	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , 2016 , 174, 103-10	4.9	70
181	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1969-1977	6.9	69
180	Each degree of glucose intolerance in pregnancy predicts distinct trajectories of β -cell function, insulin sensitivity, and glycemia in the first 3 years postpartum. <i>Diabetes Care</i> , 2014 , 37, 3262-9	14.6	68
179	Novel Diabetes Drugs and the Cardiovascular Specialist. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2646-2656	15.1	64
178	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. <i>Diabetes Care</i> , 2018 , 41, 1783-1791	14.6	63
177	Renal outcomes in patients with type 1 diabetes and macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2342-50	12.7	63
176	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c. <i>Circulation</i> , 2020 , 141, 407-410	16.7	62
175	Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3824-32	5.6	58
174	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME ² randomised trial. <i>Diabetologia</i> , 2018 , 61, 1712-1723	10.3	58
173	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018 , 17, 29	8.7	57
172	Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. <i>Diabetes Care</i> , 2017 , 40, 1756-1762	14.6	54
171	Cardiometabolic implications of postpartum weight changes in the first year after delivery. <i>Diabetes Care</i> , 2014 , 37, 1998-2006	14.6	54
170	Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. <i>American Journal of Medicine</i> , 2011 , 124, S19-34	2.4	54
169	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. <i>Circulation</i> , 2018 , 137, 2179-2183	16.7	52
168	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1128-1139	12.7	51
167	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. <i>American Heart Journal</i> , 2016 , 179, 175-83	4.9	51
166	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. <i>Circulation</i> , 2018 , 138, 2884-2894	16.7	50

165	Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers. <i>Journal of Human Genetics</i> , 1999 , 44, 10-4	4.3	49
164	Sex of the baby and risk of gestational diabetes mellitus in the mother: a systematic review and meta-analysis. <i>Diabetologia</i> , 2015 , 58, 2469-75	10.3	48
163	Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019 , 96, 489-504	9.9	47
162	The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3702-9	5.6	45
161	Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β cell function. <i>Diabetes Care</i> , 2014 , 37, 1116-23	14.6	45
160	The role of insulin in the metabolic response to exercise in diabetic man. <i>Diabetes</i> , 1979 , 28 Suppl 1, 76-81	9	45
159	Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2192-2202	6.7	43
158	Effect of Rosiglitazone and Ramipril on β -cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. <i>Diabetes Care</i> , 2010 , 33, 608-13	14.6	43
157	Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 834-844	18.1	42
156	Prospective associations of vitamin D status with β cell function, insulin sensitivity, and glycemia: the impact of parathyroid hormone status. <i>Diabetes</i> , 2014 , 63, 3868-79	0.9	41
155	Body image concepts differ by age and sex in an Ojibway-Cree community in Canada. <i>Journal of Nutrition</i> , 1996 , 126, 2990-3000	4.1	40
154	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017 , 187, 1-9	4.9	39
153	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 631-639	6.7	39
152	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020 , 43, 1546-1552	14.6	38
151	Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetes. <i>Diabetes Research and Clinical Practice</i> , 2014 , 105, 88-95	7.4	38
150	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. <i>Cell Metabolism</i> , 2019 , 30, 609-613	24.6	36
149	Determinants of reversibility of β cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013 , 305, E1398-407	6	36
148	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial. <i>Age and Ageing</i> , 2019 , 48, 859-866	3	34

147	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019 , 139, 1458-1460	16.7	34
146	Vitamin D and parathyroid hormone status in pregnancy: effect on insulin sensitivity, β cell function, and gestational diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4506-13	5.6	34
145	Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME \square . <i>Diabetologia</i> , 2018 , 61, 1522-1527	10.3	33
144	Evaluation of Circulating Determinants of Beta-Cell Function in Women With and Without Gestational Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2683-91	5.6	33
143	Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021 , 99, 750-762	9.9	33
142	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 123-31	18.1	32
141	Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. <i>Hypertension</i> , 1997 , 29, 1073-7	8.5	32
140	Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2019 , 42, 1930-1938	14.6	31
139	Longitudinal changes in estimated and measured GFR in type 1 diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 810-8	12.7	31
138	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e005875	7.6	30
137	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 126-135	12.3	30
136	Effects of Canagliflozin in Patients with Baseline eGFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 1705-1714	6.9	30
135	Blood pressure-lowering effects of incretin-based diabetes therapies. <i>Canadian Journal of Diabetes</i> , 2014 , 38, 364-71	2.1	29
134	Maternal Serum Prolactin and Prediction of Postpartum β Cell Function and Risk of Prediabetes/Diabetes. <i>Diabetes Care</i> , 2016 , 39, 1250-8	14.6	29
133	Newer insulin analogs: advances in basal insulin replacement. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15 Suppl 1, 6-10	6.7	28
132	Insulins: past, present, and future. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012 , 41, 1-24	5.5	28
131	PPAR α agonists in type 2 diabetes: how far have we come in preventing the inevitable? A review of the metabolic effects of rosiglitazone. <i>Diabetes, Obesity and Metabolism</i> , 2001 , 3, 34-43	6.7	28
130	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 713-715	7.4	27

129	Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2016 , 4, e000270	4.5	27
128	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. <i>PLoS ONE</i> , 2015 , 10, e0141085	3.7	26
127	Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. <i>Diabetes Care</i> , 2014 , 37, 1076-82	14.6	24
126	Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. <i>Diabetes Care</i> , 2011 , 34, 1601-4	14.6	23
125	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021 , 99, 999-1009	8.9	23
124	-6A promoter variant of angiotensinogen and blood pressure variation in Canadian Oji-Cree. <i>Journal of Human Genetics</i> , 1998 , 43, 37-41	4.3	21
123	Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e016976	6	21
122	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. <i>Canadian Journal of Diabetes</i> , 2016 , 40, 50-7	2.1	20
121	Rationale and design of the CAROLINA ² - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. <i>BMC Neurology</i> , 2018 , 18, 7	3.1	20
120	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. <i>Circulation</i> , 2018 , 138, 1605-1607	16.7	20
119	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020 , 43, 1803-1812	14.6	20
118	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME ² trial. <i>European Heart Journal</i> , 2020 , 41, 209-217	9.5	20
117	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2780-2782	15.1	19
116	Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. <i>Clinical Genetics</i> , 1998 , 54, 394-9	4	19
115	Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. <i>Molecular Metabolism</i> , 2019 , 20, 63-78	8.8	19
114	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 854-861	6.9	18
113	Bladder cancer in the EMPA-REG OUTCOME trial. <i>Diabetologia</i> , 2017 , 60, 2534-2535	10.3	18
112	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 1164-1173	8.4	18

111	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019 , 42, e42-e44	14.6	16
110	Two-year trial of intermittent insulin therapy vs metformin for the preservation of β cell function after initial short-term intensive insulin induction in early type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1399-1407	6.7	16
109	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018 , 138, 1599-1601	16.7	16
108	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1745-1751	6.7	15
107	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1625-1633	6.7	14
106	Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1207-1214	6.7	14
105	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 949-959	18.1	14
104	HbA _{1c} , Insulin Resistance, and β Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy. <i>Diabetes Care</i> , 2019 , 42, e1-e3	14.6	14
103	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019 , 42, e53-e55	14.6	13
102	The Relationship Between Parathyroid Hormone and 25-Hydroxyvitamin D During and After Pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1729-36	5.6	13
101	The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversary presentations. <i>Diabetes Care</i> , 2014 , 37, 8	14.6	13
100	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2020 , 43, 3007-3015	14.6	13
99	Liraglutide and Glycaemic Outcomes in the LEADER Trial. <i>Diabetes Therapy</i> , 2018 , 9, 2383-2392	3.6	13
98	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , 2017 , 40, 793-799	14.6	12
97	Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial. <i>Advances in Therapy</i> , 2015 , 32, 201-15	4.1	12
96	Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2987-95	5.6	12
95	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35, 895-897	4.3	12
94	Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. <i>Diabetes Care</i> , 2020 , 43, 1157-1163	14.6	12

93	Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum. <i>Diabetologia</i> , 2015 , 58, 1354-62	10.3	12
92	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). <i>Diabetes Therapy</i> , 2020 , 11, 53-70	3.6	12
91	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 384-395	6.9	12
90	Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. <i>Canadian Journal of Diabetes</i> , 2017 , 41, 6-9	2.1	11
89	Associations of circulating 25(OH)D with cardiometabolic disorders underlying type 2 diabetes mellitus in an Aboriginal Canadian community. <i>Diabetes Research and Clinical Practice</i> , 2015 , 109, 440-9	7.4	11
88	The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree. <i>Journal of Human Genetics</i> , 1999 , 44, 225-9	4.3	11
87	Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2487-2492	6.7	11
86	Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2019 , 16, 577-581	3.3	10
85	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Journal of the American Society of Echocardiography</i> , 2020 , 33, 644-646	5.8	10
84	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , 2020 , 38, 1829-1840	1.9	10
83	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <i>American Heart Journal</i> , 2021 , 233, 141-148	4.9	10
82	LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial. <i>Journal of Hypertension</i> , 2016 , 34, 1140-50	1.9	10
81	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1437-1444	6.7	9
80	Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>American Journal of Hypertension</i> , 2020 , 33, 1092-1101	2.3	9
79	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. <i>Metabolism Open</i> , 2020 , 7, 100039	2.8	9
78	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1141-1150	6.7	9
77	Fasting capillary glucose as a screening test for ruling out gestational diabetes mellitus. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013 , 35, 515-522	1.3	9
76	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME. <i>ESC Heart Failure</i> , 2020 , 7, 3401	3.7	9

75	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1085-1093	12.3	9
74	Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 622-630	6.7	9
73	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	8
72	Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000825	4.5	8
71	The discovery of insulin in Toronto: beginning a 100-year journey of research and clinical achievement. <i>Diabetologia</i> , 2021 , 64, 947-953	10.3	8
70	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <i>Circulation</i> , 2022 ,	16.7	8
69	Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 744-748	6.7	7
68	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017 , 40, 1302-1313	14.6	7
67	Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2335-2347	6.7	7
66	Longitudinal Associations of Phospholipid and Cholesteryl Ester Fatty Acids With Disorders Underlying Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2536-44	5.6	7
65	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 569-580	6.7	7
64	Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018 , 314, E287-E295	6	7
63	Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042909	1.2	6
62	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1151-1156	6.7	6
61	Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2450-2458	6.7	6
60	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. <i>Cardiovascular Diabetology</i> , 2019 , 18, 156	8.7	6
59	The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and B-cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	6
58	Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. <i>Cell Metabolism</i> , 2021 , 33, 740-747	24.6	6

57	Diabetes: Steno-2 - a small study with a big heart. <i>Nature Reviews Endocrinology</i> , 2016 , 12, 692-694	15.2	6
56	Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e020053	6	6
55	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 135-141	6.7	6
54	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2193-2198	6.7	5
53	Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes. <i>Journal of Lipid Research</i> , 2018 , 59, 1751-1762	6.3	5
52	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000461	4.5	5
51	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021 ,	3.7	5
50	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 200	8.7	5
49	Diabetes: Progress in reducing vascular complications of diabetes. <i>Nature Reviews Endocrinology</i> , 2014 , 10, 451-3	15.2	4
48	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME. <i>Diabetes and Vascular Disease Research</i> , 2020 , 17, 1479164120975256	3.3	4
47	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. <i>ESC Heart Failure</i> , 2021 , 8, 2603-2607	3.7	4
46	Traditional foods and 25(OH)D concentrations in a subarctic First Nations community. <i>International Journal of Circumpolar Health</i> , 2016 , 75, 31956	1.7	4
45	Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1173-1181	6.7	4
44	Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. <i>Diabetologia</i> , 2021 , 64, 1235-1243	10.3	4
43	Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1706-1714	6.7	3
42	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. <i>Diabetes</i> 2020;69:291-299. <i>Diabetes</i> , 2020 , 69, e7-e8	0.9	3
41	Serum Ferritin and Glucose Homeostasis in Women With Recent Gestational Diabetes. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 567-572	2.1	3
40	Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction. <i>Journal of the American Heart Association</i> , 2019 , 8, e014231	6	3

39	Erythropoietin and glucose homeostasis in women at varying degrees of future diabetic risk. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 26-31	3.2	3
38	Predictors and clinical implications of a false negative glucose challenge test in pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013 , 35, 889-898	1.3	3
37	Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.. <i>Circulation</i> , 2021 ,	16.7	3
36	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1652-1659	6.7	3
35	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1886-1891	6.7	3
34	Asymmetric dimethylarginine and arginine metabolites in women with and without a history of gestational diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 964-970	3.2	2
33	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , 2017 , 40, e165-e166	14.6	2
32	INTERMITTENT INTENSIVE INSULIN THERAPY FOR TYPE 2 DIABETES: EFFECTS ON HYPOGLYCEMIA, WEIGHT GAIN, AND QUALITY OF LIFE OVER 2 YEARS. <i>Endocrine Practice</i> , 2019 , 25, 899-907	3.2	2
31	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. <i>Physiology</i> , 2018 , 33, 197-210	9.8	2
30	The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort. <i>Lipids</i> , 2019 , 54, 617-627	1.6	2
29	The pharmacokinetics of insulin analogues and pumps. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001 , 18, S3-S4		2
28	Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.. <i>Diabetes Care</i> , 2022 , 45, 357-364	14.6	2
27	Alternative Routes of Insulin Delivery		2
26	Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort. <i>Diabetes Care</i> , 2021 , 44, 1682-1691	14.6	2
25	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2775-2784	6.7	2
24	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) IN A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34,	4.3	1
23	Delivery by Caesarean section and infant cardiometabolic status at one year of age. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014 , 36, 864-869	1.3	1
22	Response to comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. <i>Diabetes Care</i> 2014;37:1076-1082. <i>Diabetes Care</i> , 2014 , 37, e209	14.6	1

21	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.. <i>EClinicalMedicine</i> , 2022 , 43, 101240	11.3	1
20	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. <i>Diabetes</i> , 2020 , 69, 131-LB	0.9	1
19	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). <i>Diabetes and Vascular Disease Research</i> , 2020 , 17, 1479164120970933	3.3	1
18	Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. <i>Canadian Journal of Diabetes</i> , 2016 , 40, 379-381	2.1	1
17	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 226-236	4.5	1
16	Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease". <i>Circulation</i> , 2018 , 138, 850-851	16.7	1
15	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 568-577	7.9	1
14	Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022 , 8, e12268	6	1
13	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.. <i>Diabetes Research and Clinical Practice</i> , 2022 , 109837	7.4	1
12	Oscar B. Crofford: Clinician, scientist, educator, advocate for people with diabetes, and godfather of diabetes control and complications trial. <i>Diabetes Care</i> , 2014 , 37, 3139-42	14.6	0
11	The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.. <i>Diabetes and Metabolism</i> , 2022 , 101331	5.4	0
10	Efficacy and Safety of Inhaled Insulin Therapy. <i>Annals of Internal Medicine</i> , 2006 , 144, 533	8	0
9	Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1926-1935	6.7	0
8	Treatment of Type 1 Diabetes Mellitus in Adults 2016 , 770-787.e4		
7	Response to Comment on Retnakaran et al. Liraglutide and the preservation of pancreatic β cell function in early type 2 diabetes: the LIBRA trial. <i>Diabetes Care</i> 2014;37:3270-3278. <i>Diabetes Care</i> , 2015 , 38, e26	14.6	
6	The authors reply. <i>Kidney International</i> , 2020 , 97, 213-214	9.9	
5	Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". <i>Stroke</i> , 2017 , 48, e256-e257	6.7	
4	Response to comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. <i>Diabetes Care</i> 2014;37:1076-1082. <i>Diabetes Care</i> , 2014 , 37, e225	14.6	

- 3 Does an intensive multifactorial intervention reduce mortality in type 2 diabetes mellitus?. *Nature Clinical Practice Endocrinology and Metabolism*, **2008**, 4, 434-5
- 2 SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. *Nephrology Dialysis Transplantation*, **2018**, 33, i487-i487 4-3
- 1 PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. *Diabetes, Obesity and Metabolism*, **2001**, 3 Suppl 1, 34-43 6-7